OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Lin on Defining Biomarker-Based Treatment Approaches in NSCLC

October 4th 2023

Edwin Lin, MD, PhD, discusses the utilization of antibody-drug conjugates and the importance of defining biomarker-based approaches for this treatment class in patients with non–small cell lung cancer.

Dr Wander on the Evaluation of Vepdegestrant in ER+/HER2– Breast Cancer

October 4th 2023

Seth Wander, MD, PhD, discusses the evaluation of vepdegestrant (ARV-471), a proteolysis targeting chimera estrogen receptor degrader, in patients with advanced estrogen receptor/HER2-negative breast cancer.

Dr Spira on the Evaluation of Fianlimab Plus Cemiplimab in Advanced Melanoma

October 4th 2023

Alexander I. Spira, MD, PhD, FACP, discusses the evaluation of the LAG-3 inhibitor fianlimab plus cemiplimabin patients with advanced melanoma who were PD-L1 inhibitor–naïve, as seen in the findings from a phase 1 study.

Dr Dhodapkar on the Use of Linvoseltamab in Relapsed/Refractory Multiple Myeloma

October 4th 2023

Madhav V. Dhodapkar, MBBS, discusses efficacy and safety findings from the dose-expansion portion of the phase 2 LINKER-MM1 trial of linvoseltamab in patients with relapsed/refractory multiple myeloma.

Dr Phillips on the Evolving Treatment Landscape in MCL

October 4th 2023

Tycel Phillips, MD, discusses current and emerging therapeutic treatment strategies for patients with mantle cell lymphoma.

O'Neil on the Feasibility of Diagnostic CT-Enabled Planning For Patients Receiving Palliative Radiation Therapy

October 4th 2023

Melissa O'Neil, MRT(T), discusses findings from the randomized phase 2 Diagnostic CT-Enabled Radiation Therapy trial of palliative radiation therapy.

Dr Wong on Hypofractionation vs Conventional Fractionation in Breast Cancer Postmastectomy

October 3rd 2023

Julia S. Wong, MD, discusses findings from data presented on patient-reported toxicity results from the randomized trial of fractionation following breast reconstruction in patients with breast cancer.

Dr Davies on Challenges Experienced When Treating Patients With Multiple Myeloma

October 3rd 2023

Faith E. Davies, MD, discusses challenges experienced by hematologist-oncologists and specialist nurses when treating patients with multiple myeloma.

Dr Lonial on the Outcomes of the IKEMA Trial in Relapsed Multiple Myeloma

October 3rd 2023

Sagar Lonial, MD, FACP, discusses the final overall survival analysis of the phase 3 IKEMA trial of isatuximab when combined with carfilzomib and dexamethasone in patients with relapsed multiple myeloma, highlighting the progression-free survival and OS outcomes.

Dr Brahmer on the Investigation of FLX475 in NSCLC

October 3rd 2023

Julie Renee Brahmer, MD, discusses the investigation of FLX475 in patients with advanced non–small cell lung cancer.

Dr Deek on the Investigation of Immune Cell Infiltration in MIBC

October 2nd 2023

Matthew Pierre Deek, MD, discusses the significance of pretreatment immune cell infiltration in patients with muscle-invasive bladder cancer who had been treated with definitive chemoradiation.

Dr Hoppe on Outcomes of the CheckMate 744 Trial in Hodgkin Lymphoma

October 2nd 2023

Bradford (Brad) S. Hoppe, MD, MPH, discusses the rationale for investigating consolidative radiotherapy in place of autologous stem cell transplant in patients with low-risk, relapsed/refractory classic Hodgkin lymphoma who have been previously treated with nivolumab plus brentuximab vedotin, as investigated in the phase 2 CheckMate 744 study, as well as key findings from this trial.

Dr Chuong on the Patterns of Guided Radiation Therapy in Pancreatic Cancer

October 2nd 2023

Michael Chuong, MD, FACRO, discusses patterns of locoregional recurrence following guided radiation therapy in pancreatic cancer.

Dr Machtay on the Prognostic Value of Pre-Treatment Immunologic Biomarker Levels in NSCLC

September 29th 2023

Mitchell Machtay, MD, discusses the association between the levels of circulating immune biomarkers prior to immunotherapy and survival outcomes in patients with stage III non-small cell lung cancer.

Dr Ricciuti on PD-L1 Expression and Long-Term Survival Outcomes With PD-L1 Inhibitors in Advanced NSCLC

September 29th 2023

Biagio Ricciuti, MD, discusses the association between PD-L1 expression levels and long-term survival with anti–PD-L1 monotherapy in patients with advanced non–small cell lung cancer.

Dr Reed on Genetic Differences Between Ewing Sarcoma and Osteosarcoma

September 29th 2023

Damon R. Reed, MD, discusses the genetic differences that distinguish Ewing sarcoma from osteosarcoma, as well as unmet needs in patients with these diseases.

Dr Velázquez Mañana on Survivorship Care Needs in Older Patients With Lung Cancer

September 29th 2023

Ana Velázquez Mañana, MD, discusses findings from a study determining survivorship care needs in low-income, older patients with lung cancer.

Dr Jones on the Application of ctDNA Testing in CRC

September 29th 2023

Jeremy C. Jones, MD, discusses the applications of circulating tumor DNA testing in colorectal cancer.

Dr Chaudhary on the Utilization of Trastuzumab Deruxtecan in Metastatic HER2+ Breast Cancer

September 29th 2023

Lubna Chaudhary, MD, MS, discusses the ongoing investigation and utilization of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and compared this agent’s efficacy with that of trastuzumab emtansine.

Dr Desai on the Benefits and Limitations of Bladder Preservation With Chemoradiation in MIBC

September 28th 2023

Neil Desai, MD, discusses the potential benefits and limitations of utilizing chemoradiation or triple modality therapy for bladder preservation in the upfront management of patients with locally advanced, nonmetastatic muscle-invasive bladder cancer.